Home › Encyclopedia › PT-141 (Bremelanotide): Research Status and Trial Data
Research / Unapproved

PT-141 (Bremelanotide): Research Status and Trial Data

Drafted by an automated content engine from FDA, PubChem, ClinicalTrials.gov, NIH DSLD, and Open Beauty Facts data.

Molecular formulaC50H68N14O10
Molecular weight1025.2 g/mol
Registered trials4
PubChem CID9941379

PT-141, often studied under the name bremelanotide, comes up frequently in research and peptide discussion forums. Understanding its actual regulatory status and trial record matters before drawing any conclusions about it.

Key Takeaways

  • PT-141 (bremelanotide) is an unapproved research compound with no FDA-approved label.
  • Its molecular formula is C50H68N14O10, with a molecular weight of about 1,025.2 g/mol.
  • The compound is cataloged in PubChem under CID 9941379.
  • Four registered clinical trials have studied bremelanotide.
  • The trial sample available includes studies in women with sexual arousal and desire concerns, all marked completed.

What PT-141 Is

PT-141 is the common research name for a peptide compound also referred to as bremelanotide. It has a molecular formula of C50H68N14O10 and a molecular weight of approximately 1,025.2 grams per mole. There is no approved drug label associated with PT-141 itself, meaning no confirmed indications, dosing, or mechanism statements exist for it under this name.

Clinical Trial Landscape

Registries list four clinical trials associated with bremelanotide. Trials in the available sample examined its use in women with female sexual arousal disorder and in premenopausal women with hypoactive sexual desire disorder. Each of the sampled trials, including studies identified as NCT00425256, NCT01382719, and NCT02338960, is listed with a completed status. These records reflect registered research activity only, not confirmation of any approved use.

FAQ

What is PT-141?
PT-141 is the common research name for a peptide compound also known as bremelanotide. It does not have an FDA-approved label, so no official indications or approved mechanism statements exist for it. It is primarily discussed in the context of registered clinical trials.
How many clinical trials have studied bremelanotide?
Public registries list four clinical trials associated with bremelanotide, the compound also known as PT-141. Trials in the available sample studied its use in women with sexual arousal and desire concerns. All of the sampled trials are listed as completed.
What is the molecular structure of PT-141?
PT-141 has the molecular formula C50H68N14O10 and a molecular weight of approximately 1,025.2 grams per mole. It is cataloged in PubChem under compound identifier 9941379. This places it among larger, more complex peptide compounds.
Is PT-141 approved for medical use?
No, PT-141 does not carry an FDA-approved label under this name. It is classified as an unapproved research compound. Its documented history comes from registered clinical trials rather than approved marketing use.
What conditions have been studied with bremelanotide?
Available trial records show bremelanotide studied in premenopausal women with female sexual arousal disorder and hypoactive sexual desire disorder. These studies were conducted as registered clinical trials, not under an approved label. The compound remains investigational under this name.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication. Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.

Sources: PubChem ClinicalTrials.gov

Updated 2026-08-03